By Samuel Indyk
Investing.com – Avacta Group (LON:AVCT) has announced that a study of its AffiDX antigen lateral flow test has shown it detects the Delta variant of the SARS-CoV-2 virus in clinical samples.
The clinical data for the AffiDX test demonstrated 100% sensitivity for identifying infectious individuals with viral load measured by PCR of Ct
The test was evaluated with a small number of patient samples confirmed to be Delta variant positive, for a Ct
“We are delighted to report that the AffiDX SARS-CoV-2 antigen lateral flow test detects the Delta variant with very high sensitivity for patients with a Ct value of less than 29,” said Avacta Group CEO Dr Alastair Smith. “This is a variant of the virus that is spreading rapidly on a global scale and therefore the ability of the test to detect this variant is paramount to our commercial roll-out.”
The AIM-listed company’s test recently received its CE mark for professional use in the UK and EU and a non-exclusive commercial deal was signed with Calibre Scientific last week to distribute the test for professional users.
The company confirmed it is progressing multiple commercial opportunities with other distributors and professional end users in both the UK and EU. The test is not currently available for sale in the United States.
At 09:03BST, shares in Avacta Group were trading higher by 6.9% at 186.00 pence per share.
Avacta Group says its antigen Covid test can detect the Delta variant
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.